GPCR Stock — Structure Therapeutics Inc.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 18.6 · elevated Equity put/call 0.79

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −5%

below

Price vs 50-day avg +9%

above

RSI (14) 50

neutral

MACD trend Negative

52-week position 42%

mid-range

Momentum

relative strength

Very Weak

1-month return +2%

trailing

6-month return −44%

trailing

YTD return −29%

this year

Relative strength −51%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $45 › 200d $51 — 200d above 50d

Institutional flow Accumulating

23 of 199 funds reported for Jun 30 · net +6.9K sh shares · +5 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.91% of float · ▲ +1.3% MoM · 8.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

199 holders — near 3-yr high, broad support

Squeeze score 60

elevated · 0–100

Fundamentals

Weak

EPS growth −3%

Y/Y

Free cash flow $-225.8M

Balance sheet $799.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 120%

annualized · 1-yr

Max drawdown −62%

past year

ATR 5.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−5% Neutral

Price vs 50-day avg

+9% Bullish

RSI (14)

50 Neutral

MACD trend

Negative Bearish

52-week position

42% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $45 › 200d $51 — 200d above 50d

Institutional flow Accumulating

23 of 199 funds reported for Jun 30 · net +6.9K sh shares · +5 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.91% of float · ▲ +1.3% MoM · 8.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

199 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $16 Now $49 · 42% 52-wk high $95

vs 200-day avg -5% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and short-term investments	1.4B	as of December 31, 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
GPCR Structure Therapeutics Inc. this stock	$10.47B	-29.4%	—	—	2.9%
ONC BeOne Medicines Ltd.	$471.01B	+7.6%	+22179.2%	958.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$121.16B	+4.4%	+46.2%	28.3	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$68.78B	-15.4%	+20.8%	16.0	3.3%
ARGX Argenx SE	$57.44B	+9.9%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

200

% held: 31.7%
Reported: 23 of 199
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

146

View

Short & Settlement

Short Interest Rising

Shares short

6.2M

Days to cover: 8.8d
Change: +78.4K sh

View

Short Volume

Short vol %

65%

As of: Jul 24, 2026

Short Total

View

Fails to Deliver

FTD shares

3.6K

Value: $186.7K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

58.1%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Thomas R Carper

Amount: $1.0K–$15.0K
Traded: Oct 4, 2023

View

Financials

Net income (FY)

$-141.2M

EPS diluted: $-0.80

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 11

View

Proposed Sales

Value

$1.7M

Shares: 35.5K
Filed: Jun 25, 2026

View

Exempt Offerings

Offering

$7.0M

Filed: Jan 10, 2022

View

Earnings & Events

Earnings Calls

Last call

Jun 9, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
GPCR	+1.3%	+1.8%	-44.5%	-8.5%	-29.4%
SPY	-1.7%	+0.7%	+6.4%	-1.2%	+8.3%
vs SPY	+3.0%	+1.1%	-50.8%	-7.3%	-37.6%

GPCR · Structure Therapeutics Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance